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X-ray scatteringThis work investigates the discrimination of lipid monolayers by the ovine antimicrobial peptide SMAP-29
and compares it to that of the human LL-37 peptide. Fluid phospholipid monolayers were formed in a
Langmuir trough and subsequently studied with the X-ray scattering techniques of X-ray reﬂectivity and
grazing incidence X-ray diffraction. Any changes in the phospholipid structure after injection of peptide
under the monolayer were considered to be due to interactions between the peptides and lipids. The data
show that SMAP-29 discriminates against negatively charged phospholipids in a similar way to LL-37.
However, it is even more interesting to note that despite a higher concentration of SMAP-29 near the
monolayer, ensured by its greater charge as compared to LL-37, the amount of SMAP-29 needed to observe
monolayer disruption was around three and a half times the number of molecules of LL-37 used to see
similar changes with the same system. This result suggests that the structure, amino acid sequence or size of
the peptide may well be as important as electrical charge and therefore gives many implications for the
further study of antimicrobial peptides with regards to novel drug design and development.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The last decade has seen a considerable increase in the study of
antimicrobial peptides and their mimics due to the interest for
their potential as future pharmaceutical drug compounds [1–3].
Although it is evident that the cell membrane is a barrier which
must be overcome by antimicrobial peptides for cell disruption, the
mechanisms of action of all antimicrobial peptides remain unclear
[4]. It has been proposed that antimicrobial peptides exhibit cell
selectivity by being more toxic to micro-organisms than to host
cells [4–7]. One of the main reasons for this is thought to be due to
the different lipid components and physical properties of the cell
membranes involved.
SMAP-29 is an α-helical peptide of ovine origin [8–9] and the
sequence has been determined as: RGLRRLGRKIAHGVKKYGPTVL-
RIIRIAG [9]. The peptide has a net charge of +10 and a molecular
mass of 3257. The charges in the SMAP-29 molecule originate from
six arginine (R) residues, three lysine residues (K) and one histidine
(H) residue. The molecule only contains positively charged residues




ll rights reserved.peptide, LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
which contains both positively and negatively charged residues
[7,10–12].
Tack et al. [9] conﬁrmed the work of Bagella et al. [13] regarding
the structure of SMAP-29. They used nuclear magnetic resonance and
circular dichroism to show that SMAP-29 contains an α-helical
section followed by an extended region joined by a hinge at residues
18–19 (glycine and proline). Tack et al. [9] also showed that there
was an ordered hydrophobic section between residues 20 and 28,
and that SMAP-29 was ﬂexible in 40% triﬂuoroethanol and formed
two sets of conformers that were different with regards to their
orientation relative to the N-terminal domain [9].
SMAP-29 is active against many potent bacterial strains including
Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa,
Saccharomyces aureus and Enterococcus faecalis [8,11,14–16] but
unlike LL-37, it also has antifungal properties [8,17].
The understanding of the mechanism of interaction between
SMAP-29 and cell membranes of different types has not been fully
developed. However, there is some work investigating the effect of
SMAP-29 on cell and lipid systems with regards to cell selectivity and
its mechanism of action [8,17–19].
The mechanism of action of SMAP-29 was investigated by Lee
et al. [17]. They found that SMAP-29 accumulates in the plasma
membrane. Lee et al. [17] also carried out experiments with lipo-
somes composed of phosphatidylcholine (PC) lipids and mixtures of
PC and cholesterol to observe the disruptive effect of SMAP-29 on cell
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SMAP-29 occurs via pore formation, although the complete mecha-
nism of action is still unclear.
McGwire et al. [18] investigated the mechanisms of action of
SMAP-29 and its analogues as possible treatments for the protozoan
parasitic infection caused by Trypanosoma brucei. They found that the
peptides were effective in killing the parasite in both the insect and
bloodstream forms. According to these authors [18], the mechanism
of action against the parasite involves disruption of surfacemembrane
integrity as is the case with other microbes, such as E. coli and
S. aureus which were studied by Anderson et al. [19]. However, the
precise mechanism of action remains to be elucidated. As well as this,
previous studies on SMAP-29 have not addressed how SMAP-29 can
discriminate between different lipid types and this has been studied
with other peptides and is a major attribute of antimicrobial peptides.
The interactions of phospholipid monolayers with SMAP-29 have
not been investigated previously. However, the same lipid monolayer
systems have been used to study the interactions of the porcine
antimicrobial peptide protegrin-1 [6] and the human antimicrobial
peptide LL-37 [7] using X-ray scattering techniques. Previously pub-
lished results [7] indicate that there is very little interaction between
LL-37 and the di-palmitoylphosphatidylcholine (DPPC) monolayer at
the concentrations that were used (8.9 nM and 22.3 nM). This is in
contrast to results for the dipalmitoylphosphatidylglycerol (DPPG)
monolayer system [7] whose structure was completely destroyed
after injection of LL-37 even at the low concentration of 8.9 nM. The
work by Neville et al. [7] also supports previous research [20–23]
suggesting that the human antimicrobial peptide LL-37 acts against
bacterial membranes via the “carpet” mechanism of membrane
perturbation with consequent micellation.
The carpet mechanism of membrane perturbation [22] consists of
a process which involves the covering of the membrane surface with
peptides, progressing to direct membrane disruption or the formation
of toroidal pores followed by the possible formation of peptide-
induced peptide–lipid micelles. However, little evidence exists of the
formation of micelles induced by cathelicidin antimicrobial peptides
such as LL-37. It has been proposed that this evidence was presented
previously by Neville et al. [7], whilst studying the effect of LL-37 on
DPPG monolayers in a ﬂuid system by using epiﬂuorescence micros-
copy ([7], Fig. B6). More recently, in agreement with the previous
work on LL-37 interactions [7], Sevcsik et al. [23–24] have proposed
that LL-37 causes membrane disruption in different ways not only
depending on the type of lipid head group, but also on the hydro-
carbon chain length. Also in agreement with our ﬁndings [7], Sevcsik
et al. [23] show that themodel DPPG layer is decreased in thickness on
perturbation by LL-37. However, they propose the formation of
peptide-induced micelles with the DPPC lipid rather than DPPG. It has
been previously suggested that variation in results may be explained
by different experimental approaches [23] and therefore future work
on LL-37 interactions which combines the methodologies and model
systems usedmight be able to provide a more detailed insight into the
mechanism of action of LL-37.
The proposed molecular basis for membrane discrimination by
antimicrobial peptides [25] suggests that hydrophobic interactions
are in place in all peptide-membrane interactions but that cationic
peptides are more strongly attracted to prokaryotic membranes due
to the electrostatic forces present between the positive charged
peptides and the negatively charged bacterial membranes [25]. In this
case the initial binding, or attraction of the peptides to membranes, is
due to electrostatic interactions which play a crucial role in ensuring
an increased concentration of peptide near the membrane surface
[26–27]. Electrostatic forces may also be important during adsorption
at the membrane surface or during insertion. However, the individual
contribution of electrostatic forces during adsorption or insertion is
difﬁcult to ascertain and it has been proposed that other factors such
as peptide size, structure, hydrophobicity and charge distributionmayinﬂuence the interaction of antimicrobial peptides with different
types of membranes. Sevcsik et al. [24] have proposed that lipid net
charge is not the main factor which determines the mechanism of
action of LL-37 interactions with model membrane systems.
This paper shows that two very similar systems behave differently
when the peptide used is the main variable. Our results show that the
SMAP-29 peptide (which has a lower molecular mass and is more
cationic) interacts with negatively charged lipid monolayers to a
lesser extent than the LL-37 peptide, which has a greater molecular
mass and is less cationic, even when a 38% molar excess of SMAP-29
was used. Therefore, peptide amino acid sequence, size and confor-
mation are likely to be as important as its charge distribution.
2. Materials and methods
2.1. Materials
DPPC and DPPG lipids were purchased from Avanti Polar Lipids
(Alabaster, USA) and were used without further puriﬁcation. All
experiments were performed using Dulbecco's phosphate buffered
saline (DPBS) (Invitrogen, Carlsbad, USA) without calcium and
magnesium ions. Monolayers of DPPC were deposited from chloro-
form solution (high performance liquid chromatography grade, Fisher
Scientiﬁc, Pittsburgh, USA), whereas DPPG was deposited from a 9:1
v/v% chloroform/methanol solution (high-performance liquid chro-
matography grade, Fisher Scientiﬁc). LL-37 and SMAP-29 (90–95%
pure) were supplied by Pepceuticals (Nottingham, UK). LL-37 and
SMAP-29 peptides were provided as solid powders and made up to
stock solutions (0.1 mg/ml peptide in 0.01% glacial acetic acid w/v)
before being further diluted for the working solutions (10 μg/ml
peptide in 0.01% glacial acetic acid w/v). Acetic acid (Fisher Scientiﬁc)
was used to maintain the peptide structure while in solution.
2.2. Lipid monolayers
To investigate peptide-membrane interactions, Langmuir mono-
layers composed of lipids representative of membranes were
studied. Monolayers can be used as mimics of the outer leaﬂets of
cell membrane bilayers and this approach has been utilised
repeatedly over the years [28–33]. The planar monolayer system
allows versatile adjustments of parameters such as monolayer
composition, surface pressure, packing density and aqueous sub-
phase properties in order to model the conditions under which
peptides interact with cell membranes. The cell membranes of
different organisms have characteristic lipid compositions. However,
to develop a full understanding of membrane interactions, individual
components of membranes were studied separately to ascertain the
contribution of each membrane component to the overall interaction
of the peptide with the membrane. In this research DPPC and DPPG
were used to form Langmuir monolayers at the air–aqueous
interface to mimic the outer leaﬂet of the erythrocyte cell membrane
and the surface of the bacterial cell wall, respectively. The subphase
temperature was maintained at 22±1 °C for lateral compression and
X-ray scattering experiments.
2.3. Pressure-area compression isotherms
Upon spreading, the lipid ﬁlm was left undisturbed for 15 min to
allow time for the solvent to evaporate. At this point, barrier
compression (at 2 cm2 min−1) was initiated and the increase in
surface pressure of the monolayer was monitored until the target
pressure was attained. This compression gives rise to a surface
pressure (mN/m) versus area per lipid molecule (Å2/molecule)
isotherm, which can be utilised to observe the phases and phase
transitions associated with the monolayer as a function of area per
lipid molecule.
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Pretreatment experiments check the inserted peptide's ability to
sustain its position in the monolayer at high lipid packing densities.
In a typical pretreatment experiment, the lipid was deposited and
the solvent was left to evaporate for 15 min. While holding the
barriers at the fully expanded position, the peptide was injected
uniformly into the subphase under the monolayer using a micro-
syringe with an “L-shaped” needle (VDRL needle; Hamilton, Reno,
Nevada, USA) to make up the ﬁnal concentration required in the
subphase. Peptide concentrations of 0.04 μg/ml and 0.1 μg/ml were
used. The molar ratio of SMAP-39 to LL-37 was 1.38 to 1. They are
well below the minimum inhibitory concentration (MIC) for both
peptides used. In the case of SMAP-29 the above concentrations
correspond to 12.3 nM and 30.7 nM, respectively, and the MIC is
120–767 nM for various different types of bacteria [8,20]. For LL-37
the MIC is 0.2–28 μM and the concentrations used were 8.9 nM
(0.04 μg/ml) and 22.3 nM (0.1 μg/ml). Any change in surface pres-
sure as a result of peptide incorporation into the lipid monolayer was
monitored. The monolayer was left to equilibrate for 15 min after
peptide injection. The lipid/peptide ﬁlm was then compressed by
closing the barriers while its pressure-area isotherm was recorded.
These types of experiments have been termed “pretreatment” since
the lipid layer is “pretreated” with the peptide before compression
and the other lipid with peptide experiments carried out using the
Langmuir trough (insertion experiments) involve compression of the
lipid before peptide injection. The pretreatment experimental
method has been successfully used with lipid A monolayers [34]
and polymers [35–36], but has not been previously used to examine
the types of lipid-peptide system presented here.
2.5. Insertion experiments
Insertion experiments were carried out to quantify the interaction
of the peptide with the lipid monolayer. Initially, the lipid mono-
layer was deposited and equilibrated, followed by compression to
the surface pressure corresponding to the liquid-condensed phase
of lipids (30 mN/m), and equivalent to the packing density of real
cell membranes [37–38]. The surface pressure was kept constant via
a built-in proportional-integral-derivative control feedback system
by adjusting the surface area. The peptide solution (10 μg/ml
peptide in 0.01% glacial acetic acid w/v) was then evenly injected
underneath the monolayer in the same way as for the pretreatment
experiments to make up the required ﬁnal bulk concentration. Once
the peptide is injected, its interaction with the lipid monolayer
results in an increase in the surface area since the surface pressure
is being kept constant. The resulting relative change in area per
molecule, ΔA/A, was monitored throughout the experiment to
compare the degree of peptide insertion into the DPPC and DPPG
monolayers.
2.6. Peptides at the air–liquid interface
The peptides are soluble in water, but, being amphipathic [9,39]
are expected to be adsorbed at the air–liquid interface. SMAP-29 was
injected into the pure subphase without a lipid monolayer present.
The properties of the pure SMAP-29 monolayer were then investi-
gated using pressure-area isotherms in conjunction with X-ray
reﬂectivity (XR) and grazing incidence X-ray diffraction (GIXD) and
compared to those of the LL-37 ﬁlm [7].
2.7. Langmuir troughs
Pressure-area compression and pretreatment isotherms were
performed using a twin-barrier rectangular Teﬂon micro Langmuir–
Blodgett trough equipped with a Wilhelmy plate (Nima Technology,Coventry, UK). Insertion experiment data were obtained using a
custom-built trough [40–41] at the University of Chicago. X-ray
scattering measurements were taken at the European Synchrotron
Radiation Facility (ESRF) utilising a custom-built Langmuir trough
equipped with a single moveable barrier [28,42].
2.8. GIXD and XR
Surface X-ray scattering experimentswere carried out at the ID10B
(Troïka II) beam line at the ESRF (Grenoble, France). The trough was
completely sealed by a cover before experiments were carried out.
The oxygen level was subsequently monitored as the air inside the
covered trough system was replaced with water-saturated helium in
order to reduce evaporation and scattering from the air. The oxygen
level was allowed to reach a sufﬁciently low level before measure-
ments were commenced (b0.1%). Control measurements of pure lipid
monolayers were followed by subsequent injection of the desired
amount of peptide into the subphase under the monolayer-covered
area of the surface at 30 mN/m.
Grazing incidence X-ray diffraction (GIXD) [43] was used to
obtain in-plane information concerning the molecular structure of
surfaces [44]. GIXD measurements were made with variation of the
X-ray momentum transfer component qxy that is parallel to the air–
aqueous interface. Such a conﬁguration enables the incident wave to
be reﬂected, whereas the refractive wave propagates along the
surface, making this technique very sensitive to changes at the air–
aqueous interface. The reﬂections of the Bragg peaks observed with
this geometry can be indexed by two Miller indices, hk. Their angular
position 2θhk, corresponding to qhk=(4π/λ) sin θhk, yields the repeat
distance dhk=2π/qhk for the two-dimensional (2D) lattice structure.
Bragg peak proﬁles (intensity against qxy) were ﬁtted with Gaussians
and the peak position values were used to obtain unit-cell dimen-
sions of the lipid lattices. The observation of two Bragg peaks in the
diffraction pattern of an amphiphilic monolayer is indicative of a
distorted hexagonal unit cell (which may be better described as a
centered rectangular unit cell) [6]. Therefore, all unit-cell dimensions
in this paper have been calculated using the centered rectangular
unit cell approximation.
Specular X-ray reﬂectivity (XR) measurements reveal information
on the electron-density distribution along the surface normal andmay
be used to determine the density and thickness of thin ﬁlms
[31,43,45]. When specular X-ray reﬂectivity occurs, the scattering
vector qz may be calculated from qz=4π/λ sin α, where α is the
grazing angle of the incident beam and λ the wavelength of the X-ray
beam. The reﬂectivity curve of intensity against qz contains informa-
tion regarding the gradient of the electron-density proﬁle in the
direction normal to the surface [46–47]. XR measurements were
carried out over a range of angles corresponding to qz values of 0–
0.65 Å−1. The reﬂected beam intensity was measured as a function of
the incident angle using a position sensitive detector.
The XR data were then analysed using data processing and ﬁtting
programs as carried out previously [7,28,34], in order to gain
information on the electron density distribution in the direction
normal to the surface. This provided an electron density proﬁle
averaged laterally over both ordered and disordered parts of the
system. The whole monolayer and subphase system was modelled as
slabs, or layers, where each slab has a constant electron density and
thickness [28].
3. Results and discussion
3.1. SMAP-29 ﬁlm structure at the air–aqueous interface
Although the structure of SMAP-29 has been shown to be
unstructured in aqueous solutions [9], a peptide monolayer ﬁlm
formed at the air–aqueous interface when peptide was injected
Fig. 2. Pressure-area isotherm of DPPC with and without pretreatment with LL-37 and
SMAP-29. The LL-37 isotherm is also presented as one quarter scale on the area per
molecule axis. Liquid-expanded, Liquid-expanded–liquid-condensed and liquid con-
densed phases are represented as LE, LE-LC and LC, respectively.
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investigating the properties of SMAP-29 using X ray reﬂectivity.
X-ray reﬂectivity data for SMAP-29 (Fig. 1) were analysed [28,46]
after injection of SMAP-29 inside the buffer using a constant area of
the trough. After injection, the surface pressure increased slightly to
1 mN/m. The best ﬁt of the reﬂectivity data at 1 mN/m was obtained
using a two slab model. The ﬁtting of the data returned values of
12.6 Å and 11.1 Å for the two slabs going from the air–aqueous
interface towards the subphase, respectively. Corresponding electron
density values normalised to the electron density of the subphase
(0.337 e− Å−3) for the slabs were obtained as 1.31 and 1.04. Due to
the known [9] dimensions of the SMAP-29 molecule (approximately
26 Å×12 Å×16 Å), the data suggest that there is single SMAP-29
layer formed at the air–aqueous interface with the more hydrophilic
residues oriented towards the subphase.
The SMAP-29 XR data (Fig. 1) show similarities to LL-37 XR data
[7] as the shape of the curve of data is alike and there are no deﬁned
structural features such as can be seen for DPPC and DPPG lipids [7].
This suggests that the SMAP-29 peptide layer is disordered, as
mentioned earlier [9] and such as is seenwith other protein structures
at the air–aqueous interface [25,48].
3.2. Interaction of cathelicidin peptides with DPPC monolayers
Although the design of novel antimicrobial drugs involves
thorough testing on a variety of micro-organisms, it is also necessary
to test the cytotoxicity of the drug on the host cells. Since PC lipids are
the most abundant lipid type contained in the outer leaﬂet of human
red blood cell membranes [49], DPPC lipids were used to observe the
interactions of the antimicrobial peptides with lipid monolayers
composed of these lipids.
3.2.1. Pretreatment experiments
The pretreatment method was carried out in order to determine
whether the peptide could be forced out from its position at the
air–aqueous interface, by the competing lipids, when the pressure
was increased. The pretreatment experiments of LL-37 and SMAP-
29 systems presented here for the ﬁrst time are compared and
contrasted.
Fig. 2 shows pretreatment data for the DPPC with LL-37 and
SMAP-29 systems. Fig. 2 shows the isotherms of the pretreatment
experiments using two different concentrations of LL-37 (8.9 and
22.3 nM) and 12.3 nM SMAP-29. It also contains the π-A isotherm
for the pure DPPC lipid and pure LL-37 ﬁlm for comparison. The
pure LL-37 ﬁlm has been previously discussed and it is thought
that under compression the peptide aligns at the air–aqueous
interface in a similar manner to the PGLa peptide [7]. All measure-Fig. 1. Reﬂectivity data (squares) and corresponding ﬁt (line) of the SMAP-29 layer.ments were carried out on the same trough (Nima Technology).
The LL-37 isotherm is presented with the area per molecule scale
reduced to one quarter of its actual value, for better comparison of
data. Fig. 2 shows that injection of 8.9 nM LL-37 gave a pressure
increase of 1–2 mN/m and injection of 22.3 nM LL-37 gave a
pressure increase of around 8–10 mN/m.
The pretreatment isotherm (Fig. 2) of DPPC with LL-37 (8.9 nM),
shows that there is an increase in pressure at area per DPPC
molecule values of approximately 50 to 140 Å2/molecule, in com-
parison to the pure DPPC isotherm. It is clear that this increase in
pressure is mainly due to the LL-37 present at the air–aqueous
interface. Nevertheless, the plateau region of the lipid phase
transition of DPPC from the liquid-expanded to the liquid-expanded
liquid-condensed co-existence region can still be seen at around
8 mN/m. However, the presence of LL-37 at the interface has shifted
the phase transition to the right by around 20 Å2/molecule from the
value seen in the pure DPPC isotherm, showing that the LL-37 is
interacting with the DPPC in some way. An extra phase transition
can be seen in the data at around 25–28 mN/m and may be due to
the presence of LL-37 at the air–aqueous interface (Fig. 2).
When using the higher concentration of LL-37 (22.3 nM), there
was a substantial increase in pressure when the LL-37 was injected
under the lipid monolayer before compression. This is shown by the
vertical section of the curve (dotted line, Fig. 2). Therefore, because
of this initial pressure increase, the liquid-expanded and liquid-
expanded liquid-condensed phases observed with the lower
concentration of LL-37 (8.9 nM) are no longer present, and the
isotherm proceeds to the same phase transition seen with the LL-37
isotherm at around 25–28 mN/m. The LL-37 isotherm is discussed
further in Neville et al. [7].
The LL-37 peptide does not remain in DPPC ﬁlms at high
pressure as the pretreatment isotherm returns to values close to
those of the pure DPPC isotherm. This suggests that at higher
pressures (∼ 30 mN/m) and lower areas (∼ 45 Å2 per molecule) the
LL-37 is forced out from its position at the air–aqueous interface,
leaving a ﬁlm enriched in DPPC molecules.
The results of the DPPC with SMAP-29 pretreatment experiment
are also shown in Fig. 2. The data show that the liquid-expanded
lipid phase is present in both the pure DPPC isotherm and the DPPC
with SMAP-29 pretreatment isotherm (Fig. 2). However, the DPPC
with SMAP-29 pretreatment isotherm is shifted to the right by
approximately 25 Å2 per DPPC molecule units. This suggests that
SMAP-29 is present at the air–aqueous interface. The results show
that SMAP-29 goes to the surface at low pressures but is pushed
away from the air–aqueous interface (out of the DPPC monolayer)
Fig. 3. 3D plots of Bragg peaks (qxy) against Bragg rods (qz) as a function of intensity.
(A) DPPC 30mN/mmonolayer before injection. (B) after injection of 30.7 nM SMAP-29.
Fig. 4. X-ray specular reﬂectivity data (symbols) and corresponding ﬁts (lines)
normalised by Fresnel reﬂectivity plotted against scattering vector qz. Data of DPPC
monolayer at 30mN/m before injection (squares) and after 30.7 nM SMAP-29 injection
(triangles). For clarity the data have been offset vertically.
855F. Neville et al. / Biochimica et Biophysica Acta 1798 (2010) 851–860after compression to around 30 mN/m. This is seen from the fact
that the isotherm reverts to the same values of pressure and area as
the pure DPPC isotherm at pressures higher than 30 mN/m. Overall,
the data indicate that SMAP-29 goes to the surface when there is
space but it is not retained in the DPPC monolayer. This is similar to
the DPPC with LL-37 system, although the pretreatment data clearly
show the presence of LL-37 at the air–aqueous interface and not in
the presence of SMAP-29.
3.2.2. Insertion isotherms
Insertion isotherms with DPPC and DPPG systems using the LL-37
peptide have been previously carried out [7]. Insertion isotherms
using DPPCmonolayers showed that in general there was a very small
increase in area on injection of peptide into the subphase under
constant pressure conditions (30 mN/m) [7]. Here we present work
on the interactions of SMAP-29 with lipid monolayers where the
difference compared to previous work with LL-37 is the type and
molar concentration of peptide we have used. Therefore, it is inte-
resting to compare the insertion patterns of LL-37 and SMAP-29.
Pretreatment experiments (Fig. 2) showed that the SMAP-29 was
not retained in the DPPCmonolayer when the subphase concentration
before compression was 12.3 nM. Therefore, it was thought that itwould be even less likely to insert into a preformed DPPC monolayer
at 30mN/m and so insertion isothermswere carried out with 30.7 nM
SMAP-29.
It could be assumed that the insertion isotherm for DPPC with
30.7 nM SMAP-29 (Fig. 1S, supplementary data) should allow a
greater possible change on peptide insertion than using 12.3 nM
SMAP-29. However, even when using the higher concentration of
SMAP-29, the system showed no insertion of SMAP-29 into the DPPC
monolayer (Fig. 1S, supplementary data). The area per molecule value
remained stable, varying only slightly from the start point (Fig. 1S,
supplementary data). This suggests that the SMAP-29 peptide is not
attracted to the DPPC covered surface when the pressure of the DPPC
monolayer is 30 mN/m. This is consistent with the pretreatment
experiments (Fig. 2) which show that SMAP-29 is forced out from the
surface after pressures of higher than 30 mN/m are reached.
3.2.3. Grazing incidence X-ray diffraction
Grazing incidence X-ray diffraction measurements were taken at
30 mN/m when the lipid is in the liquid-condensed phase. In
corroboration with the pretreatment experiments (Fig. 2) and inser-
tion assays (Fig. 1S, supplementary data), little change in DPPC
packing pattern was observed following SMAP-29 injection at
30 mN/m (Fig. 3B). After injection of 30.7 nM SMAP-29 under the
DPPC monolayer (Fig. 3B), the peak positions yield d-spacings of
4.64 Å and 4.28 Å. This computes to unit cell dimensions of a=5.52 Å,
b=8.56 Å and an area per molecule of 47.2 Å2 showing little inter-
action of SMAP-29 with the phosphatidylcholine head groups, since
the area per molecule from the pure DPPC monolayer is 46.6 Å2. This
is very similar to the results of the DPPC at 30 mN/m with 8.9 nM LL-
37 system, which gave an area per molecule of 47.1 Å2 [7]. Although
the higher concentration of SMAP-29 (30.7 nM) is presented here,
the results were the same as for the lower SMAP-29 peptide injection
(12.3 nM), despite the two and half times increase in concentration.
It should be noted that the GIXD DPPC control data presented
(Fig. 3A) were previously published (Fig. 6, A1 [7]) when comparing
the DPPC monolayer before and after injection of LL-37 peptide.
3.2.4. X-ray reﬂectivity
In addition to the previous results (Figs. 2–3), XR data for the DPPC
monolayer after SMAP-29 injection show little variance from the data
for the pure DPPC monolayer (Fig. 4), This is consistent with selec-
tivity of antimicrobial peptides between host and bacterial mem-
branes. The data of the DPPC with SMAP-29 system were modelled as
a two-slab system, as was the DPPC with LL-37 system [7]. The ﬁt to
the data of the system where SMAP-29 (30.7 nM) was injected under
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monolayer [7]. The tail slab was found to be 16.1 Å thick and the
respective electron density for this layer normalised to the electron
density of the subphase (0.337 e− Å−3) was 0.92, whereas the head
slab was 7.6 Å thick with a normalised electron density of 1.33. These
values are comparable to those obtained for a pure DPPC monolayer
using XR [7] where the tail slab was 15.2 Å thick, with a normalised
electron density of 0.91 and the headgroup was 8.8 Å thick with a
normalised electron density of 1.33.
3.3. Interaction of cathelicidin peptides with DPPG monolayers
The results of the experiments using negatively charged DPPG
monolayers representing the bacterial surface layer are presented
below. DPPG lipids are substantial components of both Gram-positive
cell membranes and the inner membrane of Gram-negative bacteria.
The interactions of SMAP-29 and LL-37 with DPPG monolayers were
observed using pretreatment experiments. Insertion assays, GIXD and
XRwere further used to characterise the interactions of SMAP-29with
DPPG monolayers, and to compare the results with the previously
published DPPG monolayer with LL-37 results [7].
3.3.1. Pretreatment experiments
Fig. 5A shows the data of the pretreatment experiments carried out
for DPPG with LL-37 systems, using two concentrations of LL-37 (8.9
and 22.3 nM). Fig. 5 also shows the isotherms of pure DPPG and LL-37Fig. 5. Pressure-area isotherm of DPPG with and without pretreatment with (A) LL-37
and (B), SMAP-29. The LL-37 isotherm is also presented as one quarter scale on the area
per molecule axis. Liquid-expanded, Liquid-expanded–liquid-condensed and liquid
condensed phases are represented as LE, LE-LC and LC respectively. The beginning of
collapse of the system DPPG with 8.9 and 22.3 nM LL-37 are represented with CP1 and
CP2, respectively. The LL-37 phase transition and extra SMAP-29/DPPG phase
transition are indicated in the ﬁgure.for comparison. The lipid phase transition between the liquid-
expanded and liquid-expanded-liquid-condensed coexistence phases
is observed with the DPPG and 8.9 nM LL-37 system (9–13 mN/m), as
was also the case for the DPPC with 8.9 nM LL-37 system at appro-
ximately 6–10 mN/m (Fig. 2). However, the beginning of collapse of
the DPPG with 8.9 nM LL-37 system (CP1, Fig. 5A) can be seen at a
much earlier stage than for the equivalent DPPC system seen in Fig. 2.
In the ﬁgure CP, refers to the point at which collapse begins where the
surface tension is disrupted and there was overspill visually observed
even though complete collapse (a sudden drop in surface pressure)
was not observed until around 30 Å2/molecule.
When the pretreatment experiment for the DPPG with LL-37
(22.3 nM) system was carried out, the beginning of collapse (CP2,
Fig. 5A) was visually observed at a value of around 100 Å2 /molecule
which is much higher than the value for the pure DPPG monolayer
which begins to collapse at around 41 Å2/molecule. The data suggest
that the LL-37 binds strongly to the DPPG lipid (at both concentrations
used), and that some kind of DPPG/LL-37 complex is formed at the
air–aqueous interface. On compression there is not enough room for
this combined DPPG/LL-37 system to remain at the surface and thus
the surface ﬁlm becomes unstable and collapses. This discrimination
by LL-37 has been further corroborated by other experimental tech-
niques previously carried out [7].
For comparison with the DPPC experiment (Fig. 2), the DPPG
pretreatment experiment was also carried out with 12.3 nM SMAP-
29. The results of the DPPG pretreatment experiment (Fig. 5B) are
somewhat different to those of the DPPC experiment (Fig. 2). The
DPPG with SMAP-29 is similar to that of the DPPC with SMAP-29
pretreatment isotherm at high values of area per molecule. However,
there are two main differences after the pressure reaches appro-
ximately 15 mN/m. Firstly, the presence of an extra phase transition
is seen in the DPPG with SMAP-29 isotherm at around 33 mN/m.
This shows similarities to the pretreatment isotherm of the DPPC
with LL-37 system (Fig. 2) where it was suggested that the extra
phase transition was due to the presence of peptide at the air–
aqueous interface, although in this case the extra phase transition is
at a higher pressure value and for a smaller range in surface area
than for the DPPC system with LL-37. This suggests that when the
LL-37 is observed in the DPPC monolayer the additional phase
transition is due only to the LL-37 and that there is little interaction
with the DPPC and that for the case of the DPPG monolayer, the
SMAP-29 physically interacts with the DPPG forming a combined
DPPG/LL-37 phase transition (Fig. 5). Secondly, the pure DPPG and
DPPG with SMAP-29 isotherms (Fig. 5B) do not come close to each
other in values until a pressure of around 50 mN/m is reached and
shortly after this the pure DPPG monolayer collapses. In addition, the
isotherm of the DPPG with SMAP-29 experiment shows that the
monolayer is signiﬁcantly more stable as it can withstand compres-
sion to 70 mN/m. In contrast to this, the DPPC with SMAP-29 layer
collapsed at a lower pressure than the pure DPPC monolayer. These
data suggest stronger peptide–lipid interactions than lipid-lipid
interactions in the DPPG monolayer after SMAP-29 introduction into
the system. This is unlike the DPPG with LL-37 system (Fig. 5A)
which underwent collapse at a much earlier stage than the DPPG
alone, suggesting that although both LL-37 and SMAP-29 peptides
belong to the same family of antimicrobial peptides and are α-
helical, there are some differences between their modes of interac-
tion with membranes.
On examination of the 3D structures and peptide sequence of
LL-37 and SMAP-29, a structural analysis of the two peptides can be
carried out to help predict how they interact with lipid monolayers.
When the 3D structure of LL-37 is studied in structure-inducing
environments such as lipid vesicles [49–50], it can be seen to be
primarily α-helical, with a helix-bend-helix structure with the bend
at residues 14–16 [49]. This makes the molecule have a curved
cylindrical shape, with the hydrophobic residues residing within the
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opposite surface [51]. This would allow the peptide to insert into
the DPPG monolayer with the more hydrophilic side facing the
subphase and the more hydrophobic side facing the tail groups of
the lipid monolayer. From this 3D structure and the amino acid and
charge distribution we can predict that the peptide will insert into
the lipid monolayer via the carpet mechanism as we have sug-
gested previously [7] and as has more recently been suggested
when studying lipid vesicles [51]. In addition, the hydrophilic amino
acids coincide with the majority of the positively charged amino
acids found on the opposite side of the molecule to the hydrophobic
residues and so this is where any interactions with negatively
charged headgroups due to electrostatic forces would occur.
On analysis of the SMAP-29 structure it can also be seen to have a
hinge, (or bend) at its centre, but the two parts of the peptide either
side of the hinge have different structures where one part is α-helical
and the other is an ordered hydrophobic region [9]. Although SMAP-
29 has a similar percentage of hydrophobic residues as LL-37, it has
16% more hydrophilic residues, suggesting that the peptide may have
greater afﬁnity for the lipid headgroups and not penetrate into the
hydrocarbon lipid tail groups to the same degree as LL-37. In
addition, the SMAP-29 molecule is shorter but has a greater diameter
than LL-37. This may also be a factor as to why LL-37 seems to
penetrate lipid monolayers more disruptively than SMAP-29.
3.3.2. Insertion isotherms
Insertion isotherms with DPPC and DPPG systems using the LL-37
peptide have been previously published [7]. Insertion isotherms using
DPPG monolayers showed that there was a substantial increase in
area on peptide insertion (under constant pressure conditions at
30 mN/m) [7]. For the case of 8.9 nM LL-37 there was an increase of
approximately 40% ΔA/A which rose to around 180% ΔA/A when
22.3 nM LL-37 was used.
Fig. 6 shows the insertion assay data for the DPPG with 30.7 nM
SMAP-29 system at 30 mN/m under constant pressure conditions. It
also shows the data for the DPPG with 8.9 and 22.3 nM LL-37 system
for comparison. The increase in area of the DPPG with 30.7 nM
SMAP-29 system (Fig. 6) is similar to that of 8.9 nM LL-37 into DPPG
monolayer [7], which reaches approximately 40% ΔA/A after 10 min
(Fig. 6). However, since SMAP-29 is more cationic than LL-37 and the
fact that a higher concentration of SMAP-29 than LL-37 was used it
could be expected that there would be more insertion with SMAP-29
than LL-37. However, this was not the case and there is a lower
increase in area with insertion of 30.7 nM SMAP-29 in comparison to
insertion of the higher concentration of LL-37 [7]. This could be
attributable to a difference in peptide conformation since theFig. 6. Constant pressure insertion isotherm of DPPG at 30 mN/m with 30.7 nM
SMAP 29.number of molecules is higher in the case of SMAP-29 than in the
case of LL-37 as previously mentioned. It is known that SMAP-29 has
a hinge in its structure [9], allowing it to bend over on itself.
However, the LL-37 molecule consists of two helical regions joined
by a bend, suggesting that the LL-37 peptide remains in a more
linear structure than SMAP-29 and in this way possibly facilitating
insertion between DPPG molecules.
3.3.3. Grazing incidence X-ray diffraction
Fig. 7 shows the GIXD data before (Fig. 7A) and after (Fig. 7B–C)
SMAP-29 insertion into a DPPG monolayer at 30 mN/m at the lower
and higher concentrations of SMAP-29, respectively. A small increase
in area per molecule from 45.2 Å2 for a pure DPPG monolayer to
46.4 Å2 for the same system after insertion of 12.3 nM SMAP-29 was
observed (Fig. 7B). This small change suggests that the DPPG structure
remains largely unchanged, shown by the Bragg peaks which
demonstrate the presence of an ordered structure (Fig. 7B). It should
be noted that the GIXD DPPG control data presented (Fig. 7A) were
previously published (Fig. 6, B1 [7]) when comparing the DPPG
monolayer before and after injection of LL-37 peptide.
No Bragg peaks or rods were observed after injection of 30.7 nM
SMAP-29 under the DPPG monolayer at 30 mN/m, indicating that the
ordered structure of the DPPG monolayer was totally disrupted by
SMAP-29 (Fig. 7C). The effect of 30.7 nM SMAP-29 on the DPPG
monolayer is similar to that of theLL-37peptideat8.9nM[7].However,
the higher 30.7 nMconcentration of SMAP-29was required to have the
samedisruptive effect as LL-37 at 8.9 nM [7]. It should be noted that the
number of SMAP-29molecules present is 38% higher than the number
of LL-37 molecules at the same concentration (due to the lower mole-
cular mass of SMAP-29). This means that if the SMAP-29 at 30.7 nM
has the same effect as LL-37 (8.9 nM) on lipid monolayers, the LL-37
peptide would actually be more potent than SMAP-29 as less mole-
cules would be required to have the same result. As was suggested
from the insertion data (Fig. 6), this effective lower potency of SMAP-
29 than LL-37 may be due to the structural properties of the SMAP-29
peptide, which requires a higher concentration to have a pronounced
effect on the DPPG monolayer.
3.3.4. X-ray reﬂectivity
Fig. 8 shows the XR proﬁles for the DPPG system at 30 mN/m
before and after injection of SMAP-29 at 30.7 nM. The data ﬁtting for
the DPPGmonolayer yielded values of 18.1 Å and 5.9 Å for the tail slab
and head group slab thicknesses respectively. The normalised electron
density values for the tail and head group slabs were 0.98 and 1.55,
respectively [7]. The XR proﬁle after injection of SMAP-29 is very
different from that of the DPPGmonolayer alone (Fig. 8). This result is
similar to the DPPG with 8.9 nM LL-37 case [7] and is corroborated by
the GIXD results (Fig. 7C). However, the concentration of SMAP-29
(30.7 nM) used to disrupt the DPPG monolayer was higher than the
concentration of LL-37 (8.9 nM) needed to disrupt the monolayer to a
similar extent. The difference in concentration corresponds to nearly
three and half times more SMAP-29 molecules than LL-37 molecules.
The minimum of the experimental data curve was also shifted to a
greater qz value for the DPPG system with SMAP-29 in comparison to
the curve for the pure DPPG monolayer. However, the shift was only
0.06 Å−1 in comparison to the 0.11 Å−1 shift of the DPPG with LL-37
system [7]. Despite this difference, the shift indicates a decrease in
monolayer thickness as was seen before with the DPPG with LL-37
system [7] and as is also similar to observations by Lee et al. [52] who
studied lipid systems with alamethicin and melittin peptides.
Although the shape of the second peak has dramatically changed
(Fig. 8), it was still possible to ﬁt the data using a two-slab model. The
top slab has been modelled as the lipid tail groups with peptide
inserted slightly into the hydrocarbon tail region and the second slab
has been modelled as a mix of head groups and peptide. The ﬁt
parameters gave 16.6 Å for a thickness of the top slab (the slab closest
Fig. 7. 3D plots of Bragg peaks (qxy) against Bragg rods (qz) as a function of intensity. (A) DPPG 30mN/mmonolayer before injection. (B) DPPGmonolayer at 30mN/m after injection
of 12.3 nM SMAP 29. (C) DPPG monolayer at 30 mN/m after injection of 30.7 nM SMAP-29.
Fig. 8. X-ray specular reﬂectivity data (symbols) and corresponding ﬁts (lines)
normalised by Fresnel reﬂectivity plotted against scattering vector qz. Data of DPPG
monolayer at 30mN/m before injection (squares) and after 30.7 Nm SMAP-29 injection
(triangles). For clarity the data have been offset vertically.
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with a thickness of 5.9 Å and a normalised electron density of 1.25.
The comparison of these values of thickness and electron density with
those of the pure DPPG monolayer suggest that the peptide has fully
penetrated the DPPGmonolayer, as the tail group electron density has
increased by almost 19%, as well as the substantial decrease (24%) in
electron density in the head group slab.
In summary, the XR data show that SMAP-29 interacts strongly
with DPPG lipids. This interaction results in SMAP-29 insertion into
the DPPG monolayer. However, the extent of the interaction of the
DPPG with SMAP-29 system is less than that of the DPPG system with
LL-37, even though there are many more molecules of SMAP-29
injected into the subphase, than LL-37. These results suggest that
although SMAP-29 is more cationic than LL-37, there are other factors
which drive the lipid/peptide interactions such as peptide size, amino
acid sequence and structure.
3.4. Schematic cartoons
Analysis of the X-ray reﬂectivity data showed that the SMAP-29
ﬁlm consists of two slabs of similar thickness, the upper having a
Fig. 9. (A) Cartoon schematic of possible orientation of SMAP-29 at the air aqueous
interface at 1 mN/m. (B) Cartoon schematic of possible interactions of SMAP-29 with
DPPG monolayer at 30 mN/m.
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sented in Fig. 9A, where the orientation of the SMAP-29 molecule is
shown. The upper most part of the peptide contains more atoms than
the lower part, thus allowing for the difference in electron density of
the two slabs.
The combination of data from pretreatment experiments, insertion
assays andX-ray scattering techniques can be used in order to produce
a hypothesis of how SMAP-29 interacts with different lipid mono-
layers. It is likely that SMAP-29 interactswith the DPPCmonolayer in a
similar way to LL-37 [7] in that the peptide mostly remains in the
subphase and there is little interaction with the DPPC monolayer.
Fig. 9B shows a schematic cartoon of the proposed mode of inter-
action of SMAP-29 with a DPPG monolayer at 30 mN/m based pre-
dominantly on results from X-ray scattering data. The DPPG
monolayer has a tightly packed ordered structure at 30 mN/m. This
is disrupted after injection of 30.7 nM SMAP-29 into the subphase, as
the peptide penetrates the DPPG monolayer. The effect of SMAP-29
peptide insertion on the DPPG monolayer results in an overall
thinning of the ﬁlm and this thinning was also observed with a
DPPG with LL-37 system at the same pressure, but to a greater extent
[7]. The results suggest that it is likely that the peptide penetrates the
lipid monolayer, as was the case with the LL-37 insertion into DPPG
monolayers at 30 mN/m [7]. However, nearly three and a half times
the number of molecules of SMAP-29 were required to have a similar
effect to that of LL-37 since a concentration of 30.7 nM SMAP-29 was
needed compared to 8.9 nM LL-37 and this may be due to differences
in the structures of LL-37 and SMAP-29.
In conclusion, this is the ﬁrst study where X-ray reﬂectivity and
grazing incidence X-ray diffraction have been used to observe the
effects of the antimicrobial peptide SMAP-29 on phospholipid mono-
layers at the air–aqueous interface. The experimental techniqueswere
utilised in order to examine the principles of LL-37 and SMAP-29 cell
selectivity and to investigate their mechanism of action. It was found
that SMAP-29 discriminates against phospholipid monolayers con-
taining negatively charged lipids as LL-37 does. However, when the
interactions of two cathelicidin peptides with phospholipid mono-
layers were compared it can be seen that the LL-37 peptide has a more
potent effect than the SMAP-29 peptide. This is observed from the fact
that a higher concentration of SMAP-29 corresponding to nearly three
and a half times as many molecules of LL-37 was required to show the
same disruptive effect on DPPG monolayers. Since the SMAP-29
peptide has a higher net positive charge than LL-37, it would be
expected that the SMAP-29 peptide would be more attracted to the
negatively charged lipid monolayers and ensure a higher concentra-
tion near the monolayer compared to the bulk SMAP-29 concentra-tion and the amount of LL-37 attracted to the DPPG monolayer. If a
greater concentration of SMAP-29 at the lipid monolayer was present
it could be proposed that SMAP-29 should interact with the mono-
layer to a greater extent than the LL-37 peptide. However, this was not
the case and this suggests that peptide adsorption and interactions of
LL-37 with lipid monolayers involve other factors such as hydropho-
bicity, size and charge distribution. This suggests that antimicrobial
peptides interact with lipid monolayers and bilayers for a number of
reasons and that is still a great deal of work to be done in the area if
these peptides and their mimics are to be used as therapeutic drugs.
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